These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31773605)

  • 1. [Not Available].
    Kleefisch M; Lange C; Wedemeyer H
    MMW Fortschr Med; 2019 Nov; 161(20):39. PubMed ID: 31773605
    [No Abstract]   [Full Text] [Related]  

  • 2. In compensated cirrhosis with portal hypertension, β-blockers reduced a composite of decompensation or death.
    Korula J
    Ann Intern Med; 2019 Aug; 171(4):JC21. PubMed ID: 31426064
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevention of decompensation in cirrhosis: a new youth for β blockers.
    Levy S; Samuel D
    Lancet; 2019 Apr; 393(10181):1571-1572. PubMed ID: 30910327
    [No Abstract]   [Full Text] [Related]  

  • 4. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
    Abraldes JG; Albillos A; Bañares R; Turnes J; González R; García-Pagán JC; Bosch J
    Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study.
    Reverter E; Mesonero F; Seijo S; Martínez J; Abraldes JG; Peñas B; Berzigotti A; Deulofeu R; Bosch J; Albillos A; García-Pagán JC
    Am J Gastroenterol; 2015 Jul; 110(7):985-92. PubMed ID: 26077176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ondansetron on portal hemodynamics in liver cirrhosis.
    Tripkovic M; Kozjek F; Krizman I; Jereb J; Francetic I; Grabnar I; Mrhar A
    Int J Clin Pharmacol Ther; 2000 Sep; 38(9):436-40. PubMed ID: 11020031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension.
    Villanueva C; Albillos A; Genescà J; Abraldes JG; Calleja JL; Aracil C; Bañares R; Morillas R; Poca M; Peñas B; Augustin S; Garcia-Pagan JC; Pavel O; Bosch J
    Hepatology; 2016 Jan; 63(1):197-206. PubMed ID: 26422126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Beta-adrenergic inhibitors and portal hypertension].
    Lebrec D
    Therapie; 1985; 40(6):403-6. PubMed ID: 2868535
    [No Abstract]   [Full Text] [Related]  

  • 9. Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebo-controlled, double-blind study.
    Schepke M; Wiest R; Flacke S; Heller J; Stoffel-Wagner B; Herold T; Ghauri M; Sauerbruch T
    Am J Gastroenterol; 2008 May; 103(5):1152-8. PubMed ID: 18422814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β blockers in liver cirrhosis.
    Triantos C; Thomopoulos K; Lampropoulou-Karatza C
    Gastroenterology; 2014 Oct; 147(4):941. PubMed ID: 25171876
    [No Abstract]   [Full Text] [Related]  

  • 11. An advance in the treatment of portal hypertension?
    Wong F; Blendis L
    Gastroenterology; 2000 Apr; 118(4):802-3. PubMed ID: 10734033
    [No Abstract]   [Full Text] [Related]  

  • 12. [Advanced liver cirrhosis: beta blockers seem harmful].
    Lutz HH; Tischendorf JJ
    MMW Fortschr Med; 2014 Nov; 156 Spec no 2():35. PubMed ID: 25552015
    [No Abstract]   [Full Text] [Related]  

  • 13. Continuation of nonselective beta-blockers for patients with liver cirrhosis and hemodynamic nonresponse?
    Sauerbruch T
    Hepatology; 2017 Oct; 66(4):1362-1363. PubMed ID: 28734120
    [No Abstract]   [Full Text] [Related]  

  • 14. [Beta-blockers and portal hypertension].
    Rueff B
    Rev Prat; 1984 Apr; 34(19):979-80. PubMed ID: 6144165
    [No Abstract]   [Full Text] [Related]  

  • 15. When should the β-blocker window in cirrhosis close?
    Ge PS; Runyon BA
    Gastroenterology; 2014 Jun; 146(7):1597-9. PubMed ID: 24768679
    [No Abstract]   [Full Text] [Related]  

  • 16. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis.
    Groszmann RJ; Garcia-Tsao G; Bosch J; Grace ND; Burroughs AK; Planas R; Escorsell A; Garcia-Pagan JC; Patch D; Matloff DS; Gao H; Makuch R;
    N Engl J Med; 2005 Nov; 353(21):2254-61. PubMed ID: 16306522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacological treatment of the portal hypertension].
    Castañeda Romero B
    Rev Gastroenterol Mex; 2005 Nov; 70 Suppl 3():64-5. PubMed ID: 17471863
    [No Abstract]   [Full Text] [Related]  

  • 18. Beta-blockers to prevent gastroesophageal varices in cirrhosis.
    Post AB
    N Engl J Med; 2006 Mar; 354(12):1318-20; author reply 1318-20. PubMed ID: 16554538
    [No Abstract]   [Full Text] [Related]  

  • 19. Propranolol for portal hypertensive gastropathy: another virtue of beta-blockade?
    Muñoz SJ
    Hepatology; 1992 Mar; 15(3):554-6. PubMed ID: 1347508
    [No Abstract]   [Full Text] [Related]  

  • 20. Hemodynamic assessment of pharmacological response in the treatment of portal hypertension: a need to know.
    Grace ND
    Am J Gastroenterol; 2000 Aug; 95(8):1862-4. PubMed ID: 10950027
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.